Top Page
Bando Chemical Industries Ltd.
(5195)
Bando Chemical Industries Ltd. (5195) vs. iShares MSCI Japan ETF (EWJ)
Bando Chemical Industries Ltd. Business Overview & Revenue Model
Bando Chemical Industries Ltd. Financial Statement Overview
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 115.59B | 108.28B | 103.61B | 93.74B | 81.37B |
| Gross Profit | 32.79B | 31.03B | 29.42B | 27.66B | 24.85B |
| EBITDA | 8.25B | 13.56B | 12.76B | 11.88B | 10.98B |
| Net Income | 1.50B | 6.18B | 5.72B | 1.21B | 3.94B |
Balance Sheet | |||||
| Total Assets | 120.69B | 125.62B | 118.97B | 116.38B | 116.28B |
| Cash, Cash Equivalents and Short-Term Investments | 17.71B | 17.93B | 17.96B | 19.57B | 19.30B |
| Total Debt | 7.14B | 7.59B | 11.57B | 13.83B | 20.00B |
| Total Liabilities | 38.19B | 40.11B | 40.96B | 43.95B | 45.52B |
| Stockholders Equity | 82.13B | 85.16B | 77.66B | 72.13B | 70.49B |
Cash Flow | |||||
| Free Cash Flow | 6.50B | 9.69B | 3.99B | 5.99B | 6.27B |
| Operating Cash Flow | 10.76B | 14.06B | 7.71B | 9.59B | 10.17B |
| Investing Cash Flow | -4.19B | -4.74B | -3.98B | -534.00M | -2.77B |
| Financing Cash Flow | -6.91B | -8.96B | -6.43B | -9.94B | -3.63B |
Bando Chemical Industries Ltd. Technical Analysis
Bando Chemical Industries Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ¥91.27B | 10.85 | 3.68% | -1.05% | -23.08% | ||
75 Outperform | ¥93.14B | 17.64 | 5.27% | 0.68% | -32.97% | ||
74 Outperform | ¥98.62B | 9.95 | 3.05% | 17.37% | 58.50% | ||
74 Outperform | ¥87.25B | 12.14 | 2.58% | 17.01% | 16.10% | ||
72 Outperform | ¥70.52B | 47.50 | 4.53% | 6.76% | -76.11% | ||
69 Neutral | ¥93.64B | 10.59 | 5.31% | 7.73% | 27.77% | ||
68 Neutral | $2.52B | 13.38 | 7.40% | 4.65% | -0.87% | 8.24% |
Bando Chemical Industries Ltd. Corporate Events
Bando Chemical Industries, Ltd. announced the acquisition of 100,900 of its own shares, amounting to 165,344,993 yen, during the period from June 1 to June 30, 2025. This move is part of a broader plan approved by the Board of Directors to acquire up to 1,800,000 shares by April 30, 2026, with a maximum budget of 2 billion yen, which could impact the company’s stock value and shareholder equity.
Bando Chemical Industries, Ltd. announced the acquisition of 76,300 of its own shares, amounting to a total cost of 124,256,894 yen, as part of a broader plan approved by the Board of Directors to acquire up to 1,800,000 shares by April 30, 2026. This strategic move is aimed at optimizing the company’s capital structure and potentially enhancing shareholder value, reflecting a proactive approach in managing its financial resources.
Bando Chemical Industries, Ltd. announced the recording of ¥1,524 million in insurance claim income for the first quarter of the fiscal year ending March 31, 2026, due to hail damage at its Kakogawa Plant. This income was not included in the company’s previous financial forecast, and the company is assessing the need for revisions, which could impact its financial outlook and stakeholder expectations.
Bando Chemical Industries, Ltd. has announced a strategic move to acquire up to 1,800,000 of its own shares, representing 4.27% of its total issued shares, as part of a flexible capital policy aimed at adapting to changes in the business environment and enhancing shareholder returns. This decision, set to be executed between May 16, 2025, and April 30, 2026, reflects the company’s commitment to optimizing its capital structure and potentially increasing shareholder value.
Bando Chemical Industries, Ltd. reported a notable difference in its non-consolidated financial results for the fiscal year ending March 31, 2025, compared to the previous year. The company experienced a 5.8% increase in net sales but saw significant declines in operating profit, ordinary profit, and profit, primarily due to losses on the valuation of shares of subsidiaries and affiliates. This financial performance may impact the company’s market positioning and stakeholder confidence.
Bando Chemical Industries, Ltd. announced a significant discrepancy in its consolidated financial results for the fiscal year ending March 31, 2025, compared to the previous year. The company reported an increase in revenue but a substantial decrease in profits due to impairment losses related to a consolidated subsidiary, impacting its financial performance and potentially affecting stakeholder confidence.
Bando Chemical Industries reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a revenue increase of 6.8% to ¥115,593 million. However, the company faced a significant drop in operating profit and profit before tax, with declines of 55.2% and 60.0% respectively, due to increased costs. Despite these challenges, the company announced an increase in annual dividends per share to ¥76.00, reflecting a commitment to shareholder returns.
Bando Chemical Industries, Ltd. announced significant financial adjustments for the fiscal year ended March 31, 2025, due to impairment losses and a decline in the valuation of shares in subsidiaries and affiliates. The company recorded an impairment loss of ¥5,035 million, primarily due to delays in FDA approval affecting its subsidiary Aimedic MMT Co., Ltd., and decreased profitability in its Advanced Elastomer Products Business. Additionally, a loss of ¥4,049 million was recorded on the valuation of shares, with notable declines in the value of shares in Aimedic MMT Co., Ltd. and Bando USA, Inc. These financial adjustments have led to a downward revision of the company’s consolidated financial results forecast, with operating profit and profit attributable to owners expected to be lower than previously anticipated.